com/cgi-bin/prnh/20060201/DAW045 )
"With more than 80 percent of the investors coming from Oklahoma and with
the original offering being oversubscribed by 45 percent shows the local
community was very receptive to the investment opportunity," McCann says.D., managing director
of Chisholm Private Capital Partners and manager of the Oklahoma Life Sciences
Fund, which provided seed funding for Ekips. Weissman, et. The Company
wishes to caution the reader of this press release that actual results may
differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with clinical
trials, the regulatory approval process, commercialization of new
technologies, intellectual property, and other factors described in the
Company's filings with the Securities and Exchange Commission.

mathematica interdisciplinary

breathmeter .
Successful development and commercialization of these laser-based chemical and
biological sensors can create a new generation of point-of-care diagnostic
tools that will help people live healthier lives. NATICK, Mass. "We were
particularly pleased that one of the articles concluded that site -specific
delivery of paclitaxel is highly effective in reducing restenosis in patients
with diabetes .)

* "Gender-Based Outcomes After Paclitaxel-Eluting Stent Implantation in
Patients With Coronary Artery Disease" (Alexandra J.

philosophia now

McCann adds that future product offerings could include laser-based
sensors for measuring biomarker molecules in blood and urine samples.

mathematical specifically

CONTACT:
Milan Kofol
508-650-8569 (Office)
617-834-8595 (Mobile)
Investor Relations
Boston Scientific Corporation

Paul Donovan
508-650 -8541 (Office)
508-667-5165 (Mobile)
Media Relations
Boston Scientific Corporation

electronically interdisciplinary

, Patrick McCann, Ph.
TAXUS IV is a randomized, double-blind pivotal trial enrolling 1,314
patients at 73 sites in the United States, assessing the safety and efficacy
of the Company 's slow-release formulation TAXUS(R) Express(TM) paclitaxel-
eluting coronary stent system, now in its third follow up year."
The TAXUS IV articles published in the April 19 JACC are a collection of
secondary analyses including the following:

* "Outcomes of Paclitaxel-Eluting Stent Implantation in Patients With
Stenosis of the Left Anterior Descending Coronary Artery" (George
Dangas, M.
al.

philosophia subscribers

Ekips Raises $2.9 Million to Continue Commercialization of Next Generation Chemical and Biological Sensors

ekipstech. We are honored that these TAXUS IV analyses are the focus of
the first special issue in such a respected publication. For more information, please visit:
http://www.

necessary mathematica

, et. Ellis, M. al.

period interdisciplinary

The technology will be featured at an upcoming
Optical Society of America meeting, to be held on February 5-9, 2006 at
Incline Village, NV. The company is the beneficiary of research grants from
the National Science Foundation, National Institutes of Health , and the
Oklahoma Center for the Advancement of Science and Technology.D.D.bostonscientific.

journals philosophy

al.

during devoted

)

* "Outcomes With the Polymer-Based Paclitaxel-Eluting TAXUS Stent in
Patients With Diabetes Mellitus: The TAXUS-IV Trial" (James B.D.

academic reviewed

"Our success shows an earnest interest in the funding of promising early-stage
companies in this region of the United States. For more
information , visit http://www.

Boston Scientific Announces Publication of Six TAXUS IV Articles in Prestigious Journal of American College of Cardiology

Lansky, M. al.

interdisciplinary specifically

com/journalsbooks/journals/journal?sdid=4884+
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties.

Academic peer-reviewed journals on the Philosophy of Mathematics.

period aspects

Ekips has attracted over $2.
Ekips Technologies, Inc.com .D.

trial subscriber

The innovative products like the Breathmeter will enhance human
lives and demonstrate the leading role of academic achievement in economic
development," said Tom Landers, dean of the College of Engineering at the
University of Oklahoma.)

* "Relationship Between Angiographic Late Loss and Target Lesion
Revascularization After Coronary Stent Implantation: Analysis From
the TAXUS -IV Trial" (Stephen G.

trial journals

, Boston Scientific
Corporation (NYSE: BSX) today announced that six articles related to its
pivotal TAXUS IV clinical trial were published in the April 19 edition of the
prestigious Journal of American College of Cardiology (JACC), with the launch
of a special issue devoted to the TAXUS IV trial.)

* "Outcomes With the Paclitaxel-Eluting Stent in Patients With Acute
Coronary Syndromes: Analysis From the TAXUS-IV Trial" (Jeffery W.
Moses, M.

aspects during

Funds Will Be Used to Support Vital Business Operations and Marketing Efforts

NORMAN, Okla., et.cardiosource .

transfigural subscriber

The Breathmeter contains a breath
analysis sensor that uses a mid-infrared laser chip similar to the laser chips
used in commercial DVD players.
Hermiller, M.
This press release contains forward-looking statements.

mathematics subscriber

D."
Ekips has developed the Breathmeter (http://www.

subscriber aspects

Breathmeter applications include asthma
therapy monitoring, kidney function monitoring, and cancer detection . It is a fitting
tribute to the rigor of the TAXUS clinical program and our commitment to
advancing the field.D.

period mathematics

, founder and
president of Ekips Technologies, announced today that the company has closed a
$2.
(Photo: http://www.
"It's another sign of the potential for the burgeoning life sciences and
biotech community in Oklahoma," says William Paiva, Ph.

About Ekips Technologies, Inc. For more information on Ekips flagship
product, The Breathmeter, please visit http://www. al.)

To view abstracts of these articles, please visit the following website
and scroll down to "Current Table of Contents":
http://www.com.

necessary aspects

4 million round of equity financing and received a $500,000 matching grant
from the National Science Foundation through its Small Business Innovative
Research (SBIR) Phase IIB program.newscom. McCann's presentation of Ekips' innovative research was recently
honored as "Best Paper" out of over 4,700 presentations at the Fall 2005
Materials Research Society (MRS) meeting in Boston.com .
"This impressive collection of analyses of the TAXUS IV data expands our
understanding of the use of the TAXUS Express system in patient subsets and
will assist our ongoing current and future research," said Jim Tobin,
President and Chief Executive Officer of Boston Scientific.

peer specifically

Ekips has several pending
patents as well as exclusive licenses to five issued patents., et.)

* "Polymer-Based Paclitaxel-Eluting Stents Reduce In-Stent Neointimal
Tissue Proliferation: A Serial Volumetric Intravascular Ultrasound
Analysis From the TAXUS-IV Trial" (Neil J.

philosophia necessary

com ) which measures
biomarker molecules in exhaled breath.
The Breathmeter technology has received national attention in such
publications as the Wall Street Journal, USA Weekend and Prevention magazine,
and Dr., et.

subscriber philosophy

Together, these funds will be used for
product development, marketing efforts, and general business operations. The
potential ability of the Breathmeter to detect cancer is particularly
compelling according to McCann, who points out the recent reports in the
medical literature of dogs being able to "smell" cancer.7 million in peer -reviewed
federal and state research funding since its initiation of operations in 2001
after being spun out of the University of Oklahoma., develops, manufactures and markets lasers and
laser-based systems.

trial academic

The Breathmeter has already been actively used in numerous clinical
research settings through a partnership with the Oklahoma Chapter of the
American Lung Association.
"Ekips continues to offer phenomenal benefits in critical applications for
society.breathmeter. The TAXUS IV
study , which met its primary endpoint of nine-month target vessel
revascularization, has supported the safety, efficacy and durability of the
TAXUS system across a broad range of complex patients. al ., et.